A Single Arm Multi-center Study Investigating the at Home Administration of Trastuzumab Subcutaneous Vial for the Treatment of Patients With HER2-positive Early Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab
- Indications Early breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational
- Sponsors Roche
- 11 Oct 2016 Interim safety results of this and other four phase 3 studies presented at the 41st European Society for Medical Oncology Congress (2016).
- 02 Nov 2015 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017 as per ClinicalTrials.gov record.
- 02 Nov 2015 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017 as per ClinicalTrials.gov record.